HKEX will revise client margin multipliers and client maintenance margin rules at its derivatives clearing house to improve capital efficiency and lower market participants’ financing costs. Changes will be phased to allow an orderly transition: Phase 1 effective Sept 21, 2026; Phase 2 expected in March 2027 pending regulatory approval.

现货黄金上破4180美元/盎司，日内涨0.59%。

The National Medical Products Administration, via its priority review channel, has granted conditional approval to Chengdu Bailiduote Biopharma Co., Ltd.'s injectable monoclonal antibody Lunkangyilongtuo (trade name Yizekang). Indication: adults with recurrent or metastatic nasopharyngeal carcinoma who progressed after at least two lines of systemic chemotherapy and prior PD‑1/PD‑L1 inhibitor therapy. The approval adds a new treatment option for this patient cohort.